BLLN · BillionToOne, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| $450M – $465M | $397.41M | $305.11MG | $152.58M | $71.73M | |
| — | $114.19M | $96.65M | $71.67M | $54.42M | |
| — | $283.22M | $208.46M | $80.92M | $17.31M | |
| — | — | 68.32% | 53.03% | 24.13% | |
| — | $59.21M | $49.38M | $36.6M | $22.41M | |
| — | $180.71M | $143.05M | $91.47M | $64.39M | |
| — | $6.93M | $6.9M | $7M | $5.9M | |
| — | $239.92M | $192.44M | $128.06M | $86.8M | |
| — | $43.3M | $16.02M | -$47.15M | -$69.5M | |
| — | — | 5.25% | -30.9% | -96.89% | |
| — | $50.23M | $22.92M | -$40.15M | -$63.6M | |
| — | $41K | $95K | $2.39M | $3.27M | |
| — | $14.13M | $7.75M | $5.82M | $3.46M | |
| — | -$5.4M | -$8.26M | $5.61M | -$13.18M | |
| — | $37.91M | $7.76M | -$41.54M | -$82.67M | |
| — | $193.5K | $305K | $29K | $9000 | |
| — | $37.71M | $7.45M | -$41.57M | -$82.68M | |
| — | — | 2.44% | -27.24% | -115.27% | |
| — | — | $2.92M | -$41.57M | -$82.68M | |
| — | $35.92M | $5.66M | -$41.57M | -$82.68M | |
| USD/shares | — | $1.15 | $0.18 | -$4.12 | -$8.45 |
| USD/shares | — | $1.04 | $0.14 | -$4.12 | -$8.45 |
| shares | — | — | 15.88M | 10.08M | 9.78M |
| shares | — | — | 21.23M | 10.08M | 9.78M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $546K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 27 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Prenatal | $277,105,000 | $145,901,000 | $68,803,000 |
| Oncology | $24,953,000 | $2,944,000 | $0 |
| Clinical Trial Support and Other Services | $3,054,000 | $3,737,000 | $2,926,000 |